Isonicotinamide
Suppliers
Names
[ CAS No. ]:
1453-82-3
[ Name ]:
Isonicotinamide
[Synonym ]:
4-Pyridine carboxamide
MFCD00006432
4-pyridinecarboximidic acid
4-Pyridinecarboxamide
EINECS 215-926-2
4-(HYDROXYIMINOMETHYL)PYRIDINE
Isonicotinamide
Pyridine-4-carboximidic acid
pyridine-4-carboxamide
Chemical & Physical Properties
[ Density]:
1.2±0.1 g/cm3
[ Boiling Point ]:
334.4±15.0 °C at 760 mmHg
[ Melting Point ]:
155-157 °C(lit.)
[ Molecular Formula ]:
C6H6N2O
[ Molecular Weight ]:
122.13
[ Flash Point ]:
156.0±20.4 °C
[ Exact Mass ]:
122.048012
[ PSA ]:
55.98000
[ LogP ]:
-0.28
[ Vapour Pressure ]:
0.0±0.7 mmHg at 25°C
[ Index of Refraction ]:
1.570
[ Water Solubility ]:
191.7 g/L (37 ºC)
MSDS
Toxicological Information
CHEMICAL IDENTIFICATION
- RTECS NUMBER :
- NR9500000
- CHEMICAL NAME :
- Isonicotinamide
- CAS REGISTRY NUMBER :
- 1453-82-3
- BEILSTEIN REFERENCE NO. :
- 0002173
- LAST UPDATED :
- 199701
- DATA ITEMS CITED :
- 2
- MOLECULAR FORMULA :
- C6-H6-N2-O
- MOLECULAR WEIGHT :
- 122.14
- WISWESSER LINE NOTATION :
- T6NJ DVZ
HEALTH HAZARD DATA
ACUTE TOXICITY DATA
MUTATION DATA
- TYPE OF TEST :
- DNA inhibition
- TEST SYSTEM :
- Rodent - rat Liver
- DOSE/DURATION :
- 20 mmol/L
- REFERENCE :
- JJIND8 JNCI, Journal of the National Cancer Institute. (Washington, DC) V.61-79, 1978-87. For publisher information, see JNCIEQ. Volume(issue)/page/year: 69,1353,1982
Safety Information
[ Symbol ]:
GHS07
[ Signal Word ]:
Warning
[ Hazard Statements ]:
H315-H319-H335
[ Precautionary Statements ]:
P261-P305 + P351 + P338
[ Personal Protective Equipment ]:
dust mask type N95 (US);Eyeshields;Gloves
[ Hazard Codes ]:
Xi:Irritant
[ Risk Phrases ]:
R36/37/38
[ Safety Phrases ]:
S26-S36
[ RIDADR ]:
NONH for all modes of transport
[ WGK Germany ]:
3
[ RTECS ]:
NR9500000
[ HS Code ]:
29333999
Synthetic Route
Precursor & DownStream
Precursor
DownStream
Customs
[ HS Code ]: 2933399090
[ Summary ]:
2933399090. other compounds containing an unfused pyridine ring (whether or not hydrogenated) in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%
Articles
Br. J. Cancer 111(3) , 477-85, (2014)
Current therapies for metastatic melanoma are targeted either at cancer mutations driving growth (e.g., vemurafenib) or immune-based therapies (e.g., ipilimumab). Tumour progression also requires angi...
J. Inorg. Biochem. 140 , 236-44, (2014)
Tuberculosis has re-emerged as a worldwide threat, which has motivated the development of new drugs. The antituberculosis complex Na3[Fe(CN)5(isoniazid)] (IQG607) in particular is of interest on accou...
Faraday Discuss. 179 , 199-214, (2015)
A large variation is observed in induction times measured under equal conditions in 1 ml solutions. Ruling out experimental errors, this variation originates from the nucleation process. The induction...